Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3783MR)

This product GTTS-WQ3783MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3783MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2745MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
GTTS-WQ8074MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ13818MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ7470MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ13500MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ6779MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ2723MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ4124MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW